HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy

Overview of attention for article published in Frontiers in immunology, July 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 35,045 followers.

HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy https://t.co/4HAWYY8TNL

RT @FrontImmunol: New Research: HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy: Advanced studies hav…

RT @FrontImmunol: New Research: HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy: Advanced studies hav…

RT @FrontImmunol: New Research: HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy: Advanced studies hav…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.